A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 2,038
- 试验地点
- 24
- 主要终点
- Number of days with severe respiratory disease at hospital and/or at home
研究概览
简要总结
The aim of this study is to investigate whether vaccination of elderly with VPM1002 could reduce hospital admissions and/or severe respiratory infectious diseases in the SARS-CoV-2 pandemic .
VPM1002 is a vaccine that is a further development of the old Bacillus Calmette-Guérin (BCG) vaccine, which has been used successfully as a vaccine against tuberculosis for about 100 years, especially in developing countries. VPM1002 has been shown in various clinical studies to be significantly safer than the BCG vaccine.
VPM1002 strengthens the body's immune defence and vaccination with BCG reduces the frequency of respiratory diseases. It is therefore assumed that a VPM1002 vaccination could also provide (partial) protection against COVID-19 disease caused by the "new corona virus" SARS-CoV 2.
详细描述
Based on the evidence that BCG [Bacille Calmette-Guérin] vaccine
- can potentiate immune responses to other vaccines through induction of trained innate immunity and heterologous adaptive immunity, and
- can reduce the incidence of respiratory infections, exert antiviral effects in experimental models, and reduce viremia in an experimental human model of viral infection, it is hypothesized that BCG vaccination may induce (partial) protection against the susceptibility to and/or severity of SARS-CoV-2 infections.
VPM1002 is being developed with the aim to replace BCG by a vaccine that has a better safety profile and superior efficacy. Evidence from pre-clinical and clinical studies demonstrate that VPM1002 is safer and is more immunogenic than the existing BCG vaccine (for more information, please revert to the IB). It is therefore anticipated that VPM1002 will also perform better in reducing the severity of the symptoms of an infection with the SARS-CoV-2 than the BCG vaccine. Further, manufacturing of VPM1002 using state-of-the-art production methods will help hasten the production of millions of doses in a very short time and thus would be beneficial in the current SARS-CoV-2 pandemic situation.
The current trial will assess the efficacy and safety of VPM1002 to reduce the hospital admissions and clinical consequences of SARS-CoV-2 infections in the elderly population in the SARS-CoV-2 pandemic by modulating the immune system.
A total of 2038 adults aged 60 or above will be enrolled across involved clinical trial sites in Germany. Informed consent will be obtained from the subjects willing to take part in the trial. This will be followed by assessment of the eligibility criteria. Subjects who fulfil the inclusion/exclusion criteria will be centrally randomized in a 1:1 ratio to receive a single dose (0.1 ml) of either VPM1002 or Placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
The reconstitution of trial intervention will be done by unblinded site personnel who will not be involved in the collection or evaluation of outcome data. Administration of the trial intervention will be done by blinded site personnel.
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female adult (≥ 60 years)
- •Subject is contractually capable, able to understand information on study and has signed informed consent sheet
- •Subject has access to an internet-enabled electronic device
排除标准
- •Known active or latent Mycobacterium tuberculosis infection
- •Fever (> 38 °C) or respiratory tract infection within the past 24 hours
- •Current active viral or bacterial infection
- •Expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with ≥ 4 weeks between these vaccinations and the trial vaccination
- •Participation in another interventional study within 30 days before screening and during this study
- •Known hypersensitivity or allergy to (components of) the VPM1002 vaccine or serious adverse reactions to prior Bacille Calmette-Guérin (BCG) administration
- •Severely immunocompromised subjects, including:
- •subjects with known infection by the human immunodeficiency virus (HIV-1);
- •subjects with solid organ transplantation;
- •subjects with bone marrow transplantation;
- •subjects under chemotherapy, immunotherapy, or radiotherapy;
- •subjects with primary immunodeficiency;
- •treatment with any anti-cytokine therapies;
- •treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks;
- •History of malignancies, unless the subject has been free of the disease for ≥ 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial
- •Previous positive SARS-CoV-2 test result
- •Person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator
结局指标
主要结局
Number of days with severe respiratory disease at hospital and/or at home
时间窗: From day 0 to day 240
次要结局
- Cumulative incidence of death due to documented SARS-CoV-2 infection(From day 0 to day 240)
- Cumulative incidence of self-reported acute respiratory symptoms(From day 0 to day 240)
- Cumulative incidence of ICU admission due to documented SARS-CoV-2 infection(From day 0 to day 240)
- Cumulative incidence of death for any reason(From day 0 to day 240)
- Cumulative incidence of hospital admission due to documented SARSCoV- 2 infection(From day 0 to day 240)
- Cumulative incidence of hospital admissions(From day 0 to day 240)
- Cumulative incidence of documented SARS-CoV-2 infection(From day 0 to day 240)
- Number of days with self-reported fever (≥ 38 ºC)(From day 0 to day 240)
- Cumulative incidence of ICU admission for any reason(From day 0 to day 240)
- Number of days with self-reported acute respiratory symptoms(From day 0 to day 240)